Model for End-Stage Liver Disease (Combined MELD)
ورودیهای بالینی بیمار
حداقل ۰.۱ — حداکثر ۵۰ • واحد: mg/dL
حداقل ۰.۱ — حداکثر ۱۵ • واحد: mg/dL
حداقل ۰.۸ — حداکثر ۱۰
حداقل ۱۲۰ — حداکثر ۱۶۰ • واحد: mEq/L
حداقل ۱ — حداکثر ۶ • واحد: g/dL
حداقل ۱۲ — حداکثر ۱۲۰ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Mild Disease6–9
- Moderate Disease10–14
- Severe Disease15–19
- Very Severe Disease20–29
The Model for End-Stage Liver Disease (Combined MELD) calculates assessing gastrointestinal disease severity, endoscopic intervention urgency, and rebleeding risk. Key inputs include meld version. Scores guide timing emergent endoscopy, initiating high-dose proton pump inhibitor infusions, or obtaining surgical consultation. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Offers multiple versions of MELD for liver transplant planning and end-stage liver disease severity assessment
Clinical Indication
The Model for End-Stage Liver Disease (Combined MELD) is indicated for bedside clinical practice to support Offers multiple versions of MELD for liver transplant planning and end-stage liver disease severity assessment. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with upper or lower gastrointestinal hemorrhage, acute pancreatitis, acute liver failure, or inflammatory bowel disease. Clinical application is indicated across Endoscopy suites, emergency GI triage, acute medical floors, and hepatology services.
Limitations & Contraindications
Initial hemoglobin values in hyperacute hemorrhage may falsely appear normal prior to complete extravascular-to-intravascular fluid equilibration.
Clinical Pearls & Action Plan
Aggressive intravascular volume resuscitation and blood product support must precede diagnostic or therapeutic endoscopy.
Version-specific formulas: Original MELD = 3.78×ln(bilirubin) + 11.2×ln(INR) + 9.57×ln(creatinine) + 6.43; MELD-Na incorporates sodium; MELD 3.0 includes albumin, age, and sex adjustments
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| meld_version | string | Yes | MELD version to calculate |
| bilirubin | float | Yes | Serum bilirubin in mg/dL(mg/dL) |
| creatinine | float | Yes | Serum creatinine in mg/dL(mg/dL) |
| inr | float | Yes | International Normalized Ratio (INR) for prothrombin time |
| sodium | float | No | Serum sodium in mEq/L (required for MELD-Na and MELD 3.0)(mEq/L) |
| albumin | float | No | Serum albumin in g/dL (required for MELD 3.0)(g/dL) |
| age | integer | No | Patient age in years (required for MELD 3.0)(years) |
| sex | string | No | Patient sex (required for MELD 3.0) |
| dialysis_twice_in_week | string | No | Patient received dialysis at least twice in the past week |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 6–9 | Mild Disease | Lower mortality risk |
| 10–14 | Moderate Disease | Moderate mortality risk |
| 15–19 | Severe Disease | High mortality risk |
| 20–29 | Very Severe Disease | Very high mortality risk |
| 30–40 | Critical Disease | Extremely high mortality risk |
Evidence-Based References (EBM)
- Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70. doi: 10.1053/jhep.2001.22172.DOI: 10.1053/jhep.2001.22172
- Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003 Jan;124(1):91-6. doi: 10.1053/gast.2003.50016.DOI: 10.1053/gast.2003.50016
- Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008 Sep 4;359(10):1018-26. doi: 10.1056/NEJMoa0801209.DOI: 10.1056/NEJMoa0801209
- Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, et al. OPTN/SRTR 2021 Annual Data Report: Liver. Am J Transplant. 2023 Feb;23(2 Suppl 1):S178-S263. doi: 10.1016/j.ajt.2023.02.006.DOI: 10.1016/j.ajt.2023.02.006
- Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021 Dec;161(6):1887-1895.e4. doi: 10.1053/j.gastro.2021.08.050.DOI: 10.1053/j.gastro.2021.08.050